Repurposing Diabetes Drugs for Alzheimer's Disease Treatment

This research study explores the link between diabetes and Alzheimer's disease and how certain antidiabetic drugs can be used to treat AD. It provides an overview of the epidemiology and etiology of AD, as well as the standard of care and novel experimental therapies for AD. The study also discusses the link between T2D drugs and efficacy for AD, and describes the mechanism of action of T2D drugs individually. Desklib offers solved assignments, essays, and dissertations on this topic.

1
Title: Repurposing diabetes drugs as treatments for Alzheimer's Disease

2
Abstract
The research topic basically captures the association that exists between Alzheimer disease
and diabetes. Both of these conditions have an adverse impact on the health and well-being of
many people all around the globe. The research study primarily captures how certain anti-
diabetic drugs can be used for the purpose of treating AD in individuals. A thorough and
detailed insight has been provided onto both of the health conditions in order to show the link
that connects both of them. The key connection between diabetes and Alzheimer disease
arises due to insulin resistance and deficiency. The research study has been designed to
address how diabetic drugs can be used for the purpose of treating Alzheimer disease in
individuals.
Introduction
Type 2 diabetes and Alzheimer disease (AD) are considered as the two most common
diseases in the aging population. It has been estimated that around 5.4 million people in
United States suffer from AD and the risk of this disease increase with the age. According to
the study of Yarchoan & Arnold, (2014), one in the eight people above the age of 65 and
every one in two people above the age of 85 years suffer from AD. WHO has also recognised
the increasing complexity of the dementia and have also acknowledged that all countries
should consider dementia as a critical public health problem. AD is considered as the most
common form of dementia, in which people suffer from progressive deterioration of memory
along with other problems related to cognitive functioning (Lee & Krishnan, 2010). The
report of WHO has identified that “In Singapore, the number of people afflicted by the
condition is expected to rise from about 22,000 currently to about 53,000 in 2020 and
187,000 in 2050” (WHO, 2017, p. 2).
Similarly, the occurrence of type 2 diabetes among the population is also very high. Yarchoan
& Arnold, (2014) have identified that around 90% of the aging population of US suffer from
type 2 diabetes and similar statistics have been identified in other developing nations as well.
Therefore type 2 diabetes and AD are significant public health issues that affect the quality of
life of the individuals. Akter et al. (2011) has argued that there is a significant link between
diabetes and Alzheimer disease, as they result in many social and health related
consequences.

3
Epidemiology of Alzheimer disease
According to the study of Reitz, Brayne, & Mayeux, (2011), more than 25 million people all
over the world suffer from dementia and the most common form of dementia is Alzheimer's
disease. In developed, as well as developing nations, Alzheimer's disease has significant
consequences and significantly affect the individuals, caregivers and healthcare providers.
According to the report of Alzheimer Disease Association Singapore, dementia is a
progressive intellectual decline and it has been identified that in the year 2018 around 50
million people around the world were affected by dementia. This number is also expected to
increase to 82 million 2030 and 152 million by 2050 (Alzheimer Disease Association, 2018).
According to this information around 82,000 people in the year 2018 will be affected by
dementia and this number can increase to 1000,000 in few years (Alzheimer Disease
Association, 2018). The financial strain caused by the disease worldwide is very high and had
cost around US$1 trillion. According to the study of Woo, Thompson, & Magadi (2017), in
Singapore, dementia has resulted in costing S$2.8 billion in the year 2015, which is estimated
to increase three time by 2030.
Qiu, Kivipelto, & von Strauss, (2009) have identified that most of the people suffering with
dementia around the world are mainly suffering from AD and there is an increase of 5 million
cases every year. The WiSE study conducted by Subramaniam et al. (2015), conducted a
comprehensive single phase, cross-sectional, epidemiological survey for understanding the
prevalence of dementia and Ad in Singapore. The study adopted the 10/66 protocol with the
Diagnostic and Statistical Manual of mental disorders -fourth edition (DSM-IV) for the
diagnosis of dementia among the population. According to the results of the study of), it was
identified that prevalence of 10/66 dementia is 10% in the older population (75 years and
above), while the prevalence of DSM-IV dementia was found to be 4.6%. The WiSE study
the likelihood of dementia increases with age. such as “for those aged 75–84 years was 4.3
times and for those 85 years and over, it was 18.4 times higher compared to that of elderly
aged 60–74 years” (Institute of Mental Health, 2015b, p. 1).
Etiology of Alzheimer’s Disease
Alzheimer’s Disease is considered as the most common form of dementia. This disease is
mainly characterised by the mitochondrial impairment, oxidative stress, synaptic dysfunction
and disruption of the blood brain barrier. This impairment are mainly caused by the abnormal

4
extracellular accumulation of amyloid-β peptide (Aβ) in the form of amyloid plaques and
aggregation of tau protein in intracellular neuro fibrillary tangles (NFTs) (Reitz, Brayne, &
Mayeux, 2011), which are considered as the hallmark of AD causing neuronal and synaptic
loss, increasing cognitive dysfunctions, loss of memory and normal body functions.
According to the study of Peric and Annaert, (2015), Ad could be of two types based on the
age of onset and pathological factors.
Another hypothesis is Tau protein deposition in the insoluble forms results in the loss of tau
function. This further results in instability of microtubule and promotes neurodegeneration.
Studies have identified that microtubule instability is a significant reason of AD (Kalra, and
Khan, 2015). Therefore, there are some significant causes of neurodegenerative disorder, that
may include genetic mutation, misfolding of protein, generation of the toxic molecules and
oxidative stress, mitochondrial dysfunction, neuro-inflammatory process and protein
degradation pathways. All of these causes are also associated with type 2 diabetes and its
pathological conditions.
Pathology of AD
Dementia is a disorder that is characterised by the deterioration of the cognitive functioning
and increasing behavioural problems. Alzheimer disease (AD) is considered as the most
common cause of Dementia. According to the study of Perry and Perry (2015) the pathology
of AD largely remains a mystery for most of the scholars and scientists. More focus has been
placed on brain, while the disease mainly takes place on cellular level. According to the study
of Reitz, Brayne, & Mayeux, (2011), the main pathological change that has been identified in
the AD brain tissue are that the level of both amyloid-β (Aβ) peptide is increased, which is
deposited extracellularly in diffuse and neuritic plaques. Also, hyperphosphory-lated tau (p-
tau), which is a microtubule assembly protein that mainly accumulated intercellularly as
neurofibrillary tangles (nFts) (Reitz, Brayne, & Mayeux, 2011).
Perry and Perry (2015) have also identified that molecular changes occurring due to aging in
the individuals led to altering the metabolism and biochemistry of individual pathways.
Addition to these pathologies, AD is also characterised by the widespread loss of synapses
and neurons. According to Ferrarelli (2018), Alzheimer’s disease (AD) is a complex
neurodegenerative disease, which is further characterised by the progressive loss of cognitive
functioning and dementia. Ferrarelli (2018) argued that “formation of plaques (focal
aggregates) of the protein amyloid-β (Aβ) in the brain is frequently observed in AD patients,

5
as are acetylation and aggregation of the protein tau and loss of the prolyl isomerase Pin1”
(p. 1).
Standard of care / therapies for AD
Cholinesterase inhibitors is considered as the most significant part for the treatment of the
patients suffering with AD. For the treatment of mild to moderate AD, four drugs have been
approved including, donepezil, galantamine, rivastig-mine, and tacrine (Apostolova 2016).
This therapy is also considered as significant standard of care for the patients suffering with
AD. The ChEIs are considered as clinically beneficial in the double blinded, placebo control
trials. However, the recent reviews have informed that ChEIs including rivastigmine and
galantamine do not have much clinical benefits than donepezil. The recent studies have
shown that Acetylcholinesterase inhibitors (AChEIs) and memantine remain the only
important drugs that are used for the treatment of AD. It is also required that patient continue
these therapies for long terms for benefits, as the benefits can be seen on the severe level of
the illness as well (Bishara et al. 2015).
Novel experimental therapies for AD
According to the evidences, Alzheimer's disease (AD) is considered as a significant
healthcare problem in the developed and developing nations. The novel treatments and
pharmacotherapies are mainly based on the amyloidogenic hypothesis of AD, which informs
that beta amyloid (Aβ) peptide is mainly responsible for cognitive impairment in patients
with AD (Mahajan 2015). Therefore, the main goal of the novel treatment approaches is to
reduce the production of Aβ through the inhibition of β and γ secretase enzymes and to
enhance the mechanism of dissolution of the existing cerebral Aβ plaques (Folch et al. 2016).
The novel treatment strategies include cleavage of amyloid precursor protein (APP) by α-
secretase, which is also considered as the disease modifying strategy for AD (Mahajan 2015).
Link between T2D drugs and efficacy for AD
There are various studies that have provided the epidemiological evidences linking type 2
diabetes and its related conditions, like obesity, metabolic syndrome and hyperinsulinemia,
with Alzheimer’s disease (Beydoun et al. 2008; Li, Song, & Leng 2015). The main link of
type 2 diabetes and AD is associated with insulin resistance and deficiency. The first clue that
informs that how the brain may become insulin resistant in AD explains that Aβ oligomers

6
get binds to hippocampal neurons and results in triggering the dendritic insulin receptor
substrates (IRs) from the plasma membrane (Zhao et al 2008), which was significantly
identified in the brain of the individual suffering from AD (Moloney et al. 2010).
Some important characteristics of type 2 diabetes identified in the diabetic patients include
lower levels of insulin, IGF and IRs, which were also observed the results of neuropathology
of the patients suffering with AD (Craft 2012). Another significant link between AD and type
2 diabetes is clear with the significant increase in the biomarkers if the peripheral insulin
resistance in the hippocampus of non-diabetic AD patients identified by Talbot et al (2012).
Similarly, LI, SONG, AND LENG, (2015) have identified that abnormal activation of the
TNF-α/c-Jun N-terminal kinase pathway and inhibition of IRs-1 in cultured hippocampal
neurons is caused by Aβ oligomers in Ad patients (Arnold et al. 2018). Some of the scholars
have also considered that AD could be characterised as the “insulin resistant brain state” or
even as the “type 3 diabetes” (Bekkering et al. 2013).
Figure 1: Role of Insulin Resistance and Insulin Deficiency in Pathology of AD (Li,
Song, And Leng, 2015)
According to the study of Devi et al (2012), the accumulation of Aβ is accelerated by the
streptozotocin-induced insulin-deficient diabetes. This take place through the translational
upregulation of the β-secretase enzyme, BACE1, and its substrate, amyloid precursor protein,
in a transgenic mouse model of AD identified by Devi et al (2012). Another potential link
between the mechanism of the type 2 diabetes and AD is the interference of insulin with
extracellular proteolytic Aβ degradation occurs via the insulin-degrading enzyme, which also
further results in catabolising the IGF and insulin (Devi et al 2012; Moloney et al 2010; Li,
Song, And Leng, 2015). Under the type 2 diabetes and insulin resistance condition, it has
been identified that insulin can result in inhabiting the insulin-degrading enzyme and may
result in degradation of the Aβ, resulting in increasing neurotoxicity and increasing AD.
Besides affecting Aβ, insulin deficiency and insulin resistance can also result in increasing

7
the tau protein phosphorylation due to the activation of glycogen synthase kinase-3β (GSK-
3β) (Vanleuven 2011).
Figure 2: Mechanism of Link Between Alzheimer’s disease and type 2 diabetes mellitus
(Li, Song, And Leng, 2015)
Description of the T2D drugs and mechanism of action individually
Studies have identified that insulin can result in moderating the Aβ protein precursor
expression and also helps in processing both in vivo and in vitro. According to the study of
Li, Song, And Leng (2015) “Insulin and IGF-1 inhibited Aβ production through Akt-
mediated phosphorylation/inactivation of glycogen synthase kinase-3βand prevented
abnormal intracellular accumulation of Aβ by increasing its extracellular secretion in the
brain and accelerating its trafficking from the Golgi and trans-Golgi network to the plasma
membrane” (p, 557). The study further identified that Insulin and IGF-1 also helps in
preventing the accumulation of Aβ by facilitating the transport of the Aβ-binding carrier
proteins in the brain including albumin and transthyretin (Baker et al. 2011).
According to Freiherr et al (2013), insulin can be given intranasally to the cognitively
impaired individuals, as in this form it reaches quickly to central nervous system across
olfactory and trigeminal perivascular channels and axonal pathways. Study conducted by
Craft et al (2012) has also argued that intranasal insulin has resulted in improving the
cognitive functions and delayed memory and enhance the functions of the brain.
Another important drug used in the treatment of type 2 diabetes is Metformin orally active
biguanide. The mechanism of action that this drug involves is that it reduces the blood

8
glucose levels by suppressing the hepatic glucose output increasing the intestinal use of
glucose, increasing insulin-mediated glucose disposal and decreasing the oxidation of fatty
acids (Femminella et al. 2017). Study conducted by Li, Song, and Leng (2015) has identified
that “It also reduces insulin levels, inflammation and thrombosis, and the risks of metabolic
syndrome and diabetes in persons without diabetes” (p. 554).
Studies have identified that inflammation and insulin resistance are significant in the
pathogenesis of AD. Therefore, Thiazolidinediones (peroxisome proliferator-activated
receptor-γ) (PPARγ) agonists and potent insulin sensitizers could be significant in treating
inflammation. Thiazolidinediones have anti-inflammatory properties and its mechanism
“involves stimulation of the action of PPARγ in response to changes in insulin, thereby
triggering a drop in serum glucose” (Li, Song, and Leng 2015, p. 555). The mechanism of
Thiazolidinediones encompasses the stimulation of the actions of PPARγ, which occurs in
response to insulin and brings a decrease in the level of serum glucose (Risner et al. 2006).
Objectives
The main objective of this systematic review is to determine the if type 2diabetes drugs can
be effective in treating Alzhemier’s Disease and could be significant in reducing the
abnormal characteristics of AD, such as:
1. Preventing amyloid plaque build up
2. improving cognitive function
3. Enhancing memory and
4. Improving quality of life of individuals suffering from AD.
Material and Methods
Study Flow Diagram:
Identified Medline
Abstracts (n=8437)
Identified NCBI Abstracts
(n=7233)
Abstracts not selected for
full text review (n=8454)
Total Abstracts (n= 15670,
including Duplicates)

9
Inclusion and Exclusion Criteria: This systematic review of literature has included only
peer reviewed studies and published reports of health departments, health institutions and
government bodies for providing the correct statistics and data. Unpublished studies,
published thesis or dissertations, online articles etc are excluded from the research.
List of Articles included in the study containing the data / actual trails for the results
section:
The following research studies and articles have been used in the result section to get a
thorough insight into the research topic relating to repurposing diabetes drugs as treatments
for Alzheimer's disease.
Author Title Year Method Result
Craft Alzheimer disease: insulin
resistance and AD—
extending the
translational path
2012 Experimental
study
Provided the
animal model
for amyloid-
related brain
insulin
resistance
Craft et al Intranasal insulin therapy 2012 Pilot Clinical Discussed the
Full Text Article Review
(n=500) Excluded (n=657)
Articles Reporting on Type
2 Diates and AD (n=175)
Articles Identified in
Updated Search (n=5)
Articles Identified from
Hand Searching (n=12)
Articles Not Reporting AD
(n=127)
Eligible Article Reporting
T2DM and AD (n=48)

10
for Alzheimer disease and
amnestic mild cognitive
impairment: a pilot
clinical trial.
Trial significance of
the intranasal
insulin therapy
for the
treatment of
AD.
Craft et al Effects of regular and
long-acting insulin on
cognition and Alzheimer’s
disease biomarkers: A
pilot clinical trial.
2017 Pilot Clinical
Trial
Discussed the
effect of long-
term use of
insulin on the
cognitive
functioning of
the patients
suffering from
AD.
Dhamoon
and Nobel
Intranasal insulin
improves cognition and
modulates β-amyloid in
early AD.
2009 Review of
Literature
Provide
evidences from
epidemiologic
and
translational
research
related to
association of
diabetes and
dementia.
FEMMINE
LLA et al
Antidiabetic drugs in
Alzheimer’s disease:
Mechanisms of action and
future perspectives
2017 Review of
literature
Review of
evidences on
the mechanism
of action of
anti-diabetic
drugs and their
use for treating
AD.
Li, Song,
and Leng,
Link between type 2
diabetes and Alzheimer’s
disease: from
epidemiology to
mechanism and treatment
2015 Review of
Literature
Provides the
comprehensive
evidences for
linking T2DM
with AD and
different
therapeutic
actions for AD.
Reger et al Intranasal insulin
improves cognition and
modulates β-amyloid in
early AD
2007 Randomised
Control Trial-
Pilot study
Identified
significance of
intranasal
insulin for AD
patients and
considered
intranasal
peptide
administration

11
as novel
treatment for
degenerative
diseases.
Koenig et al
Effects of the Insulin
Sensitizer Metformin in
Alzheimer’s Disease: Pilot
Data from a Randomized
Placebo-Controlled
Crossover Study
2017 Randomized
Placebo-
Controlled
Crossover Study
The metformin
drug can
enhance the
executive
functioning of
an individual
with AD
Risner et al Efficacy of rosiglitazone
in a genetically defined
population with mild-to-
moderate Alzheimer's
disease
2006 Randomised
control trial
Identified the
significance of
rosiglitazone
for treating
AD.
Results
Link Between Type 2 Diabetes and Alzheimer’s Disease
Studies have identified that type 2 diabetes and Alzheimer’s Disease have similar
pathological components. This is the reason that some scholars have called Ad as the type 3
diabetes. Evidences have also informed that type 2 diabetes is significantly associated with
increased risk of cognitive impairments. Both diseases have become the significant public
health concern all over the world, as very large number of aging populations around the
world, suffers from type 2 diabetes and AD. Diabetes affect the neurons and brain synaptic.
In Ad also the patients suffer from the loss of brain functions, decreased cognitive
functioning, loss of memory and inability in carrying out activities of daily life. The results of
this systematic review of literature informs that determining and identifying the link between
type 2 diabetes and AD can significantly help in developing the treatment strategies and
interventions that could address the similar pathological complexities of both diseases.
In type 2 diabetes, patients suffer from high blood sugar levels, which are caused by insulin
resistance and due to which body becomes unresponsive to insulin hormone. Although,
studies have identified that acute administration of insulin may improve the memory
domains. However, the studies have also identified that delayed memory process could also

12
occur due to chronic administration of insulin. Insulin signalling is an important brain
function that helps in taking up of glucose and results in producing the insulin degrading
enzyme (IDE) in order to reduce the glucose level from the body. IDE plays a significant role
in degradation of both insulin as well as amyloid beta (Aβ) protein. Therefore,
hyperinsulinemia could result in causing the competitive inhibition for IDE-dependent
Aβ degradation and can result in increasing the production of Aβ and can lead to Aβ plaque
accumulation. Therefore, the result of the studies displays a strong link between type 2
diabetes and AD.
Evidences informed that in diabetes, the alteration in the insulin signalling occurs that results
in reducing the IDE production and further resulting in reducing the degradation of Aβ and
therefore, this mechanism results in abnormal accumulation of Aβ in brain causing plaques
that result in affecting the cognitive functions, memory and loss of ability to carry out
activities of daily life. Increasing the insulin signalling has been identified as an important
approach that can help in reducing Aβ accumulation in Hippocampus and Cortex. Aβ
clearance is significant for preventing plaque accumulation, therefore, insulin has been found
to be significant in enhancing Aβ clearance. The deposition or the accumulation of Aβ can be
significantly increased by impaired insulin signalling caused by AD. Therefore, there is a
significant and important link between type 2 diabetes and AD, which may require the special
approach and strategies for the treatment of AD.
The research study primarily focuses on three types of anti-diabetic drugs that can be used for
treating Alzheimer’s disease in patients. The main drugs that have been highlighted in this
section are Intranasal Insulin, Metformin, and Rosiglitazone. The details relating to the
dosage of the drug, the duration of the dosage, the changes that have been observed in the
patients, the dosage design and the total number of patients that were tested have been
highlighted in the below table. A brief description relating to the specific anti-diabetic drugs
have also been presented to understand how they play a key role to treat Alzheimer’s disease
in individuals.
Drug – Intranasal Insulin
Researc
hers
Diabetic
Drug
Durati
on of
dosage
Change in
patient
Dosage
design
Total
patients
(profile)
Description of
the drug
Craft et
al (2012)
Intranasal
Insulin
4
months
Improvement
in activities
of daily life
Patients
received
placebo,
The test was
conducted as
a double-
The Intranasal
Insulin is the
hormone insulin

13
ow-dose (20
IU), or
high-dose
(40 IU)
intranasal
insulin.
blind
randomised
control trial
on 104
adults.
which is
administered
through a nasal
spray to a
patient. It plays
a vital role to
regulate the
level of blood
sugar in an
individual. This
drug has been
selected for the
research
purpose, as it
plays a key role
to treat people
with
Alzheimer’s
disease. The
drug basically
reduces the level
of the insulin in
the body and
thus the level of
the insulin
signaling in the
patient’s brain is
also reduced to a
certain extent.
The drug is
generally given
via the nasal
passage as it
helps in entering
the patient’s
bloodstream
directly.
https://alzheimer
snewstoday.com
/nasal-insulin/
Drug – Metformin
Researcher
s
Diabetic
Drug
Duratio
n of
dosage
Change in
patient
Dosage
design
Total
patients
(profile)
Description of
the drug

14
Koenig
(2017)
Metformi
n
1 week
initially
8 weeks
in total
Display of
lower rate of
cognitive
impairment. It
impacts the
neuronal
networks of
the brain and
leads to
functional
preservation. It
reduces tau
phosphorylatio
n in patients.
Orally
given to
patients
Metformin
– 500 mg
daily. Then
daily
dosage is
increased
by 500 mg
until the
maximum
of 2000
mg/d
Not
disclosed
Metformin is a
biguanide
antihyperglycem
ic agent that is
used for the
purpose of
treating the non-
insulin
dependent
diabetes
mellitus. It is a
popular drug
that is used by
physicians as it
improves
glycemic
control. This is
done by
reducing the
level of hepatic
glucose
production. This
drug also plays a
vital role to
reduce the level
of glucose
absorption and
increase the
level of the
insulin-mediated
glucose uptake.
This drug is
given to the care
users in the form
of tablets. These
anti-diabetic
drugs mainly
come in the
strengths – 500
mg, 850 mg,
1000 mg/1.
https://www.dru
gbank.ca/drugs/
DB00331
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476214/
Drug – Rosiglitazone

15
Researcher
s
Diabetic
Drug
Duratio
n of
dosage
Change in
patient
Dosage
design
Total
patients
(profile)
Description of
the drug
Risner et al
(2006)
Rosiglitaz
one
6
months
treatme
nt
Participants in
APOE-ε4-
negative
patients on 8
mg
rosiglitazone
showed
improvement
on the basis of
Alzheimer’s
Disease
Assessment
Scale-
cognitive
subscale.
The dosage
of
rosiglitazon
e 2, 4, or 8
mg
500
participants
in total
with
suffering
from mild
to
moderate
Alzheimer’
s Disease
Rosiglitazone is
an anti-diabetic
drug that belongs
to the class of
glitazones. This
drug basically
functions by
activating the
intracellular
receptor section
of the peroxisome
proliferator-
activated
receptors. It has a
vital impact on
insulin resistance.
In addition to
this, it also has an
anti-inflammatory
impact. When
they are given to
the patients, the
dosage is mainly
in the form of
tablets which
could have a film
coating on them.
These anti-
diabetic drugs
mainly come in
the following
strengths – 2 mg,
4 mg, and 8 mg.
The oral
consumption of
the drug is given
to diabetic
patients.
https://www.drug
bank.ca/drugs/DB
00412
The anti-diabetic drugs that have been captured here can play a vital role to treat Alzheimer's
Disease in patients. The proper dosage and the duration of the dosage play a vital role to
make sure that the medicines react effectively with the body of the patients. The research

16
studies that have been referred to highlight the significance of anti-diabetic drugs to treat and
manage the degree of Alzheimer's Disease in individuals. The vital details relating to the
three drugs namely Intranasal Insulin, Metformin, Rosiglitazone have been captured in the
table.
The forest plot (meta-analysis) cannot be carried out. The results that have been highlighted
here are based on the systematic review as the meta-analysis was not possible.
Repurposing the Diabetes Drug as Treatment for Alzheimer’s Disease
Study conducted by Reger et al (2008) and Dhamoon and Noble (2009) have identified that
giving the intranasal insulin to the patients suffering with mild to moderate cognitive
impairment for a certain period of time can improve the cognitive and functional status of the
patients suffering with AD. Craft et al (2012) conducted the double-blind randomised control
trial of 104 adults suffering from AD, received the placebo, ow-dose (20 IU), or high-dose
(40 IU) intranasal insulin for the period of 4 months. The study informed that participants
who received either dose of insulin demonstrated improvement in memory, which was
assessed through Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-
Cog) and also displayed improvement in activities of daily life. The benefits of the insulin
were not only seen after the experiment, but continued even after the 2 months after the
experiment. Similar findings were demonstrated by the study of Craft et al (2017) that
considered intranasal insulin to be significant for long term effect and treatment of AD.
Although, some of the studies have shown that intranasal insulin treatment could cause
serious consequences, such as it may lead to chronic hyperinsulinemic conditions and the
brain may result in promoting brain insulin resistance. Therefore, it may significantly require
to explore more avenues of diabetic treatment.
Another significant drug used for the treatment of type 2 diabetes is Metformin. This drug is
also considered as significant in lowering the risk of certain cancers with the long-term use.
Although, the mechanism of action of this drug is not known, yet it has been identified that
patients suffering with type 2 diabetes and AD, receiving metformin display lower rate of
cognitive impairment in comparison to untreated patients (Femminella et al. 2017). The
results of the systematic review of the studies suggest that type 2 diabetes medications affect
the neuronal networks of the brain and also leads to functional preservation, which provide
benefit to the patients suffering with AD. The evidences from the preclinical data have

17
suggested that when metformin is administered orally, it can quickly cross the blood-brain
barriers and accumulates in the central nervous system at different levels.
The evidences included in the systematic review informs that in the vitro experiments on the
neuronal cell lines, under the prolonged condition of hyperinsulinemia, the treatment
provided through metformin therapy has displayed improvement in re-sensitize insulin
signalling. This insulin signalling helps in preventing the molecular and pathological changes
that occur in AD neurons. One of the significant characteristics of AD brain is the abnormal
deposition and aggregated proteins in the final pathway, which is also similar in most of the
neurodegenerative diseases. AD is the disease, which is characterised by the extra-neuronal
deposition of amyloid β (Aβ) protein in the form of plaque, which is also called as amyloid
plaque. In AD there is also an increase in intraneuronal aggregation of the microtubule-
associated protein tau, which is identified in the form of filaments. Therefore, the studies
have identified that the use of diabetes drugs and mainly metformin can help in reducing tau
phosphorylation, which is one significant pathological feature of AD.
Therefore, the studies reviewed in the above sections have informed that drugs used for the
treatment of diabetes could be significant in treating AD. The studies have also shown that
there is an important link between type 2 diabetes and AD. The patients suffering from type 2
diabetes are at higher risk of AD because of the changes in the brain that are caused due to
insulin resistance or insulin deficiency in diabetes. Many case control studies have shown that
though the use of antidiabetic medications and the long-term use of sulfonylureas,
thiazolidinediones, or insulin could not alter or prevent the risk of AD in diabetic patients, but
they can significantly help in improving the cognitive functioning and can reduce the amyloid
plaque build-up. Although, there are some studies like one conducted by IMFELD, et al
(2012) that reported that patients who are chronically treated with metformin display increase
in AD, yet some studies have informed that use of metformin can help in delaying loss of
memory and cognitive function. The studies have also informed that use of metformin in
comparison to placebo can help in bringing significant verbal memory score in patients
suffering with AD. Therefore, the results of this study have shown that the use of diabetic
medication or drugs could be a potential treatment for AD.
The evidences have shown that Thiazolidinediones is a significant drug for treating diabetes
that helps in reducing the serum glucose and also have potent anti-inflammatory properties.
The study conducted by Li, Song, and Leng (2015) identified that best characterised PPARγ

18
agonists are pioglitazone and rosiglitazone. Study conducted by Risner et al (2006) has
conducted a large trial that included 500 participants suffering from mild to moderate AD.
The participants of the study were randomised for the 6 months treatment with rosiglitazone
2, 4, or 8 mg. Risner et al (2006) identified that participants in APOE-ε4-negative patients on
8 mg rosiglitazone displayed improvement on the basis of Alzheimer’s Disease Assessment
Scale-cognitive subscale. However, the Phase III trial of the rosiglitazone in the case of
participants suffering from mild to moderate AD, did not display any improvements.
The evidences from the literature has informed that the three metabolic hormones that are
used in the diabetes treatment could show promising results in treatment of AD. These
hormones include GLP-1, amylin, and leptin. The evidences have shown that these hormones
are structurally different and unrelated to insulin and each of these hormones binds to
independent receptors in the human brain, and therefore, results in evading the insulin
signaling impairment. After these hormones bind to their respective receptors, they result in
activating the signalling pathways that join with the insulin-signalling pathway and also
further facilitates insulin signalling. Another significant feature of these hormones is that all
of them cross the blood-brain barrier. Another advantage of these agents and the use of
metformin is over the use of insulin is that they do not cause significant side-effects, such as
hypoglycaemia and therefore, could be effectively administered in relatively high doses.
Studies have identified that Amylin hormone binds with the independent receptors in the
brain, which is significant for activating signalling pathways that is in coverage with insulin
signalling. The studies inform that Amylin activates the production of the protein which is
AKT. This protein is required for appropriate regulation of GSK-3, which is also a protein
that leads to increased production of amyloid beta plaques and hyper phosphorylated tau.
Therefore, Amylin can be significant in reducing or preventing the building up of the plaque.
Another significant chemical is Leptin, which regulates the central nervous system and also
regulates the consumption of food and expenditure of energy. However, the recent studies
have identified the neurological effect of Leptin. Leptin is significantly expressed in the areas
of the brain that are used in memory and learning. Various characteristics of AD are regulated
by Leptin, such as Leptin directly helps in activating AMP- dependent kinase (AMPK),
which has the significant ability of modulating tau phosphorylation. Therefore, the result of
this systematic review informs that leptin activity is directly involved in regulating the
amyloid beta uptake and tau phosphorylation. These are considered as two important

19
impaired pathological features of AD. Therefore, use of Leptin could be significant treatment
modality.
Discussion
This research is based on providing a systematic review of the literature for understanding if
the drugs used for treating diabetes could be effective in treating Alzheimer’s disease. The
systematic review has been carried out by conducting a systematic search of the medical
databases and identifying the highly significant and high-quality peer reviewed studies. The
evidence included in the study inform that type 2 diabetes and AD, both are significant public
health issues that affect the healthcare cost and quality of life of individuals. The
epidemiological data gathered from the studies have shown hat there are millions of people,
who are suffering from diabetes and dementia. The most common form of diabetes is type 2
diabetes and most common form of dementia that affect people is AD. The risk of both
diseases increases with age and the rapidly aging population o developed nations has resulted
in increasing the prevalence and incidences of type 2 diabetes and AD. The evidences inform
that one in every eight people older than 65 years and one in every two older than 85 years
suffer from AD. Type2 diabetes also accounts for 90% of all the diabetes cases in US.
Earlier studies had identified that diabetes is a chronic disease that affect cognitive function
or brain functions and also reduce the quality of life of individuals. The studies included in
this review has also informed that individuals suffering from type 2 diabetes, often suffer
from reduced brain functions, poor cognitive functions and memory loss. However, through
the evidences it is clear that patients with type 2 diabetes are at increased risk of developing
AD. The ethology and pathological data of AD has also informed that there is a significant
pathological and pathogenetic link between type 2 diabetes and AD. The results of this study
inform that type 2 diabetes is characterised by insulin resistance, causing neuro inflammation,
synaptic dysfunction and cognitive dysfunctions, which is also considered as the hallmarks of
AD. Insulin resistance and other metabolic changes caused due to type 2 diabetes are
significantly associated with AD.
Therefore, the drugs used for treating type 2 diabetes can also be used for the treatment of
AD. However, every novel treatment and the use of anti-diabetic drugs have their benefits as
well as complexities. Therefore, this study proposes more significant and comprehensive test
of individual drugs in large population. The use of insulin in intranasal form can help in

20
reducing the insulin resistance and thus can further help in reducing plaque accumulation.
However, chronic use of insulin can cause brain to become insulin resistant. Therefore,
further research is recommended. Blood glucose level is associated with cognitive decline;
therefore, non-pharmacological treatment could be beneficial for both diabetes and AD.
Although, there are many diabetes drugs, which are clinically used, yet which therapy is most
effective in preventing or reducing AD is still unclear and warrants further research.
Link between Alzheimer’s disease and diabetes – valid or not
The results that have been arrived at by conducting the research study show that there is a
vital association between Alzheimer’s disease and diabetes. At first these two medical
conditions might seem quite differ from one another but in reality there exist a number of
similarities between them. A growing body of evidence suggests that both the medical
conditions are linked with impaired glucose homeostasis and affected or altered brain
function. This is the reason why certain diabetic drugs can be used for the purpose of treating
the Alzheimer’s disease in individuals. The numerous research studies that have been referred
highlight the valid link between the two medical conditions. Studies indicate that the common
thread that links diabetes with Alzheimer’s disease is the hyperglycemia along with the
insulin resistance that take place in the brain of an individual (Kresser Institute, 2019).
Potential impact of using diabetic drug for Alzheimer’s disease
The wide range of research papers and published articles that have been referred indicate that
certain diabetic drugs can be used for managing Alzheimer’s disease in people. A number of
studies have highlighted the fact that the acute administration of insulin may enhance the
memory domains in the elderly population. These drugs can have a protective impact on the
brain of the patients that suffer from Alzheimer’s disease (Ibrahim & Hassan, 2018). Thus
specific anti-diabetic medication can have a constructive implication on the mental health and
the functioning of the brain of individuals with the Alzheimer’s condition. The individuals
with Alzheimer’s disease when treated with diabetic drugs showcase a considerable fewer
signals relating to the medical condition such as disregulated gene expressions and abnormal
microvasculature expressions (Ibrahim & Hassan, 2018).
Impact on the healthcare cost
The amount of healthcare cost can be reduced to a certain degree if diabetic drugs can be
used for Alzheimer’s disease. The cost of treating Alzheimer’s disease is quite high. For

21
instance in the United States of America, the overall cost relating to the medical condition in
the year 2017 was estimated to be around $ 259 billion and it is expected that by the year
2050, the figure could touch $ 1.1 trillion (Ibrahim & Hassan, 2018). By using effective
diabetic drugs, the overall cost burden associated with Alzheimer’s disease can be curtailed to
a certain degree. According to experts, the multi-receptor drugs that were created for treating
type 2 diabetes have been shown to have uniform neuroprotetctive impact on individuals with
Alzheimer’s disease. This sign is quite promising as it shall not just constructive influence the
health outcome but it can help to favourably impact the healthcare cost as well.
Conclusion
Type 2diabetes and Alzheimer’s disease are two chronic illness that increases with age. AD is
the most common form of dementia, and the current treatment options and standard of care
may provide marginal benefits to the patients. The study identified that there are many novel
treatment approaches for AD. However, very limited treatment therapies are utilised and
more novel approaches are required. A growing body of the research related to pathological,
epidemiological and preclinical studies suggest that AD and type 2 diabetes share common
cellular and molecular mechanism. Brain insulin signalling is a significant aspect of brain
function that controls the level of insulin and serum glucose in the body. The dysfunction of
insulin signalling increases the level of glucose and also increases the accumulation of
amyloid plaque (which is the main characteristic of AD).
Therefore, targeting the insulin signalling with the help of pharmacological therapies used for
type 2 diabetes could a compelling approach for the treatment of AD. The therapeutic agents
that are originally developed for treating type 2diabetes could display significant potential in
treating insulin signalling in AD. The evidences included in this research has shown that
main drugs used in treating diabetes, such as insulin, metformin, leptin and amylin etc, could
be promising approaches for treating AD. The use of hormones poses no risk of inducing
hyperinsulinemia; therefore, it can help in activating the product of insulin signalling
pathway. These treatments can help in enhancing the cognitive function, memory function,
and can also improve the quality of life of individuals suffering from AD. This systematic
review of literature, therefore, provides comprehensive evidences about the benefits of
diabetes drugs for the treatment of AD.

22
References
1. AKTER, K., LANZA, E. A., MARTIN, S. A., MYRONYUK, N., RUA, M., &
RAFFA, R. B. 2011. Diabetes mellitus and Alzheimer's disease: shared pathology and
treatment?. British journal of clinical pharmacology, 71(3), 365-376.
2. ALZHEIMER DISEASE ASSOCIATION. (2018). Dementia in Singapore. Retrieved
3 February, 2019 from: http://alz.org.sg/dementia/singapore/
3. AMERICAN DIABETES ASSOCIATION, 2013. Standards of medical care in
diabetes—2013. Diabetes care, 36(Suppl 1), p.S11.
4. APOSTOLOVA, L.G., 2016. Alzheimer disease. Continuum: Lifelong Learning in
Neurology, 22(2 Dementia), p.419.
5. ARNOLD, S.E., ARVANITAKIS, Z., MACAULEY-RAMBACH, S.L., KOENIG,
A.M., WANG, H.Y., AHIMA, R.S., CRAFT, S., GANDY, S., BUETTNER, C.,
STOECKEL, L.E. AND HOLTZMAN, D.M., 2018. Brain insulin resistance in type 2
diabetes and Alzheimer disease: concepts and conundrums. Nature Reviews
Neurology, 14(3), p.168.
6. BAKER, L.D., CROSS, D.J., MINOSHIMA, S., BELONGIA, D., WATSON, G.S.
AND CRAFT, S., 2011. Insulin resistance and Alzheimer-like reductions in regional
cerebral glucose metabolism for cognitively normal adults with prediabetes or early
type 2 diabetes. Archives of neurology, 68(1), pp.51-57.
7. BEKKERING, P., JAFRI, I., VAN OVERVELD, F.J. AND RIJKERS, G.T., 2013.
The intricate association between gut microbiota and development of type 1, type 2
and type 3 diabetes. Expert review of clinical immunology, 9(11), pp.1031-1041.
8. BEYDOUN, M.A., LHOTSKY, A., WANG, Y., FORNO, G.D., AN, Y., METTER,
E.J., FERRUCCI, L., O'BRIEN, R. AND ZONDERMAN, A.B., 2008. Association of
adiposity status and changes in early to mid-adulthood with incidence of Alzheimer's
disease. American journal of epidemiology, 168(10), pp.1179-1189.
9. BISHARA, D., SAUER, J. AND TAYLOR, D., 2015. The pharmacological
management of Alzheimer's disease. Progress in Neurology and Psychiatry, 19(4),
pp.9-16.
10. CHEN, C., XU, X., CHEW, E., HENRY, C.J. AND KOO, E.H., 2017. Singapore
intervention study to prevent cognitive impairment and disability (singer)
initiative. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 13(7),
p.P1222.

23
11. CRAFT, S., 2012. Alzheimer disease: insulin resistance and AD—extending the
translational path. Nature Reviews Neurology, 8(7), p.360.
12. CRAFT, S., BAKER, L.D., MONTINE, T.J., MINOSHIMA, S., WATSON, G.S.,
CLAXTON, A., ARBUCKLE, M., CALLAGHAN, M., TSAI, E., PLYMATE, S.R.
AND GREEN, P.S., 2012. Intranasal insulin therapy for Alzheimer disease and
amnestic mild cognitive impairment: a pilot clinical trial. Archives of
neurology, 69(1), pp.29-38.
13. CRAFT, S., CLAXTON, A., BAKER, L.D., HANSON, A.J., CHOLERTON, B.,
TRITTSCHUH, E.H., DAHL, D., CAULDER, E., NETH, B., MONTINE, T.J. AND
JUNG, Y., 2017. Effects of regular and long-acting insulin on cognition and
Alzheimer’s disease biomarkers: A pilot clinical trial. Journal of Alzheimer's
Disease, 57(4), pp.1325-1334.
14. DEVI, L., ALLDRED, M.J., GINSBERG, S.D. AND OHNO, M., 2012. Mechanisms
underlying insulin deficiency-induced acceleration of β-amyloidosis in a mouse
model of Alzheimer's disease. PLoS One, 7(3), p.e32792.
15. DHAMOON, M.S. AND NOBLE, J.M., 2009. Intranasal insulin improves cognition
and modulates β-amyloid in early AD. Neurology, 72(3), pp.292-294.
16. ETTARO, L., SONGER, T. J., ZHANG, P., & ENGELGAU, M. M. 2004. Cost-of-
illness studies in diabetes mellitus. Pharmacoeconomics, 22(3), 149-164.
17. FEMMINELLA, G.D., BENCIVENGA, L., PETRAGLIA, L., VISAGGI, L., GIOIA,
L., GRIECO, F.V., DE LUCIA, C., KOMICI, K., CORBI, G., EDISON, P. AND
RENGO, G., 2017. Antidiabetic drugs in Alzheimer’s disease: Mechanisms of action
and future perspectives. Journal of diabetes research, 2017.
18. FREIHERR, J., HALLSCHMID, M., FREY, W.H., BRÜNNER, Y.F., CHAPMAN,
C.D., HÖLSCHER, C., CRAFT, S., DE FELICE, F.G. AND BENEDICT, C., 2013.
Intranasal insulin as a treatment for Alzheimer’s disease: a review of basic research
and clinical evidence. CNS drugs, 27(7), pp.505-514.
19. FERRARELLI, L. K. 2018. New connections: Amyloid-β in the pathology of
Alzheimer’s disease. Sci. Signal., 11(522), eaat6003.
20. FERRARELLI, L. K. 2017. New connections: Amyloid-β, calcium, and the
synapse. Sci. Signal., 10(487), eaao3024.
21. FOLCH, J., PETROV, D., ETTCHETO, M., ABAD, S., SÁNCHEZ-LÓPEZ, E.,
GARCÍA, M.L., OLLOQUEQUI, J., BEAS-ZARATE, C., AULADELL, C. AND

24
CAMINS, A., 2016. Current research therapeutic strategies for Alzheimer’s disease
treatment. Neural Plasticity, 2016.
22. INSTITUTE OF MENTAL HEALTH. 2015a. Results of the Well-being of the
Singapore Elderly Study Specialist Treatment Programmes for OCD. Accessed 3
February, 2019 Available at:
https://www.imh.com.sg/uploadedFiles/Publications/IMH_Link/IMH%20Link
%20Apr%20-%20Jun%202015.pdf
23. INSTITUTE OF MENTAL HEALTH. 2015b. Media Release. Accessed 3 February,
2019 Available at:
https://www.imh.com.sg/uploadedFiles/Newsroom/News_Releases/23Mar15_WiSE
%20Study%20Results.pdf
24. IMFELD, P., BODMER, M., JICK, S.S. AND MEIER, C.R., 2012. Metformin, Other
Antidiabetic Drugs, and Risk of Alzheimer's Disease: A Population‐Based Case–
Control Study. Journal of the American Geriatrics Society, 60(5), pp.916-921.
25. IBRAHIM, O.H.M. AND HASSAN, M.A., 2018. The Use of Anti-Diabetic Drugs in
Alzheimer’s Disease, New Therapeutic Options and Future
Perspective. Pharmacology & Pharmacy, 9(06), p.157.
26. KOENIG, A.M., MECHANIC-HAMILTON, D., XIE, S.X., COMBS, M.F.,
CAPPOLA, A.R., XIE, L., DETRE, J.A., WOLK, D.A. AND ARNOLD, S.E., 2017.
Effects of the insulin sensitizer metformin in Alzheimer’s disease: Pilot data from a
randomized placebo-controlled crossover study. Alzheimer disease and associated
disorders, 31(2), p.107.
27.KRESSER INSTITUTE. (2019). The Link between Diabetes and Alzheimer’s Disease
| Kresser Institute. [online] Available at: https://kresserinstitute.com/the-link-
between-diabetes-and-alzheimers-disease/ [Accessed 18 Mar. 2019].
28. KALRA, J. AND KHAN, A., 2015. Reducing Aβ load and tau phosphorylation:
Emerging perspective for treating Alzheimer's disease. European journal of
pharmacology, 764, pp.571-581.
29. LEE, T. S., & KRISHNAN, K. R. 2010. Alzheimer’s disease–the inexorable
epidemic. Ann Acad Med Singapore, 39(7), p.505.
30. LI, X., SONG, D. AND LENG, S.X., 2015. Link between type 2 diabetes and
Alzheimer’s disease: from epidemiology to mechanism and treatment. Clinical
interventions in aging, 10, p.549-560.

25
31. MAHAJAN, M.M., 2015. Novel therapies for treatment of Alzheimer’s
Disease. IJPR, 5(7), p.150.
32. MAYEUX, R., & STERN, Y. 2012. Epidemiology of Alzheimer disease. Cold Spring
Harbor perspectives in medicine, a006239.
33. MOLONEY, A.M., GRIFFIN, R.J., TIMMONS, S., O’CONNOR, R., RAVID, R. and
O’NEILL, C., 2010. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in
Alzheimer's disease indicate possible resistance to IGF-1 and insulin
signalling. Neurobiology of aging, 31(2), pp.224-243.
34. NG, C. S., TOH, M. P. H. S., KO, Y., & LEE, J. Y. C. 2015. Direct medical cost of
type 2 diabetes in Singapore. PLoS One, 10(3), e0122795.
35. PERIC, A. AND ANNAERT, W., 2015. Early etiology of Alzheimer’s disease:
tipping the balance toward autophagy or endosomal dysfunction?. Acta
neuropathologica, 129(3), pp.363-381.
36. PERRY E A, PERRY G. 2015. Cellular Pathology of Alzheimer Disease. Cell Dev
Biol 4:e134. doi:10.4172/2168-9296.1000e134
37. QIU, C., KIVIPELTO, M., & VON STRAUSS, E. 2009. Epidemiology of
Alzheimer's disease: occurrence, determinants, and strategies toward
intervention. Dialogues in clinical neuroscience, 11(2), p.111-128.
38. REGER, M.A., WATSON, G.S., GREEN, P.S., WILKINSON, C.W., BAKER, L.D.,
CHOLERTON, B., FISHEL, M.A., PLYMATE, S.R., BREITNER, J.C.S.,
DEGROODT, W. AND MEHTA, P., 2008. Intranasal insulin improves cognition and
modulates β-amyloid in early AD. Neurology, 70(6), pp.440-448.
39. REITZ, C., BRAYNE, C., & MAYEUX, R. 2011. Epidemiology of Alzheimer
disease. Nature Reviews Neurology, 7(3), p.137.
40. RISNER, M.E., SAUNDERS, A.M., ALTMAN, J.F.B., ORMANDY, G.C., CRAFT,
S., FOLEY, I.M., ZVARTAU-HIND, M.E., HOSFORD, D.A. AND ROSES, A.D.,
2006. Efficacy of rosiglitazone in a genetically defined population with mild-to-
moderate Alzheimer's disease. The pharmacogenomics journal, 6(4), p.246.
41. SAHADEVAN, S., SAW, S. M., GAO, W., TAN, L. C., CHIN, J. J., HONG, C. Y.,
& VENKETASUBRAMANIAN, N. 2008. Ethnic differences in Singapore's dementia
prevalence: the stroke, Parkinson's disease, epilepsy, and dementia in Singapore
study. Journal of the American Geriatrics Society, 56(11), p.2061-2068.
42. SUBRAMANIAM, M., CHONG, S. A., VAINGANKAR, J. A., ABDIN, E., CHUA,
B. Y., CHUA, H. C., ... & JEYAGURUNATHANA, A. 2015. Prevalence of dementia

26
in people aged 60 years and above: results from the WiSE study. Journal of
Alzheimer's Disease, 45(4), 1127-1138.
43. SUZANNE, M., 2012. Contributions of brain insulin resistance and deficiency in
amyloid-related neurodegeneration in Alzheimer’s disease. Drugs, 72(1), pp.49-66.
44. TALBOT, K., WANG, H.Y., KAZI, H., HAN, L.Y., BAKSHI, K.P., STUCKY, A.,
FUINO, R.L., KAWAGUCHI, K.R., SAMOYEDNY, A.J., WILSON, R.S. AND
ARVANITAKIS, Z., 2012. Demonstrated brain insulin resistance in Alzheimer’s
disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and
cognitive decline. The Journal of clinical investigation, 122(4), pp.1316-1338.
45. VANLEUVEN, F., 2011. GSK3 and Alzheimer’s disease: facts and
fiction…. Frontiers in molecular neuroscience, 4, p.17.
46. WHO. 2017. WORLD HEALTH ORGANIZATION AND ALZHEIMER’S
DISEASE INTERNATIONAL SAY DEMENTIA MUST BE A GLOBAL HEALTH
PRIORITY: New Report Calls on Nations to Recognise Dementia as a Public Health
Crisis. Retrieved 3 February, 2019 from:
http://alz.org.sg/wp-content/uploads/2017/04/Report-WHO-ADI-Dementia-Health-
Crisis.pdf
47. WINBLAD, B., AMOUYEL, P., ANDRIEU, S., BALLARD, C., BRAYNE, C.,
BRODATY, H., ... & FRATIGLIONI, L. 2016. Defeating Alzheimer's disease and
other dementias: a priority for European science and society. The Lancet
Neurology, 15(5), p.455-532.
48. WOO, L. L., THOMPSON, C. L., & MAGADI, H. 2017. Monetary cost of family
caregiving for people with dementia in singapore. Archives of gerontology and
geriatrics, 71, 59-65.
49. YARCHOAN, M., & ARNOLD, S. E. 2014. Repurposing diabetes drugs for brain
insulin resistance in Alzheimer disease. Diabetes, DB_140287.
50. YIANNOPOULOU, K.G. AND PAPAGEORGIOU, S.G., 2013. Current and future
treatments for Alzheimer’s disease. Therapeutic advances in neurological
disorders, 6(1), pp.19-33.
51. ZHAO, W.Q., DE FELICE, F.G., FERNANDEZ, S., CHEN, H., LAMBERT, M.P.,
QUON, M.J., KRAFFT, G.A. and KLEIN, W.L., 2008. Amyloid beta oligomers
induce impairment of neuronal insulin receptors. The FASEB Journal, 22(1), pp.246-
260.

27